USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS
This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.
1 - 97 . (canceled)
98 . A method for treatment of negative symptoms of a mental disorder in a subject, the method comprising administering to the subject cannabidiol (CBD), wherein the negative symptoms are selected from the group consisting of: avolition or apathy; anhedonia; asociality;
and/or disturbance of attention, and wherein the CBD is administered as a monotherapy or as an adjunct therapy to a typical or an atypical antipsychotic.
99 . The method of claim 98 , wherein the typical or atypical antipsychotic is selected from the group consisting of: aripiprazole, olanzapine, risperidone, amisulpride, quetiapine, clozapine, flupentixol, zuclopentixol, paliperidone, and zisprasidone.
100 . The method of claim 98 , wherein the typical or atypical antipsychotic is olanzapine, quetiapine or aripiprazole or a metabolite thereof.
101 . The method of claim 99 , wherein the typical or atypical antipsychotic is olanzapine, quetiapine or aripiprazole or a metabolite thereof.
102 . The method of claim 98 , wherein the mental disorder is schizophrenia or a related psychotic disorder.
103 . The method of claim 99 , wherein the mental disorder is schizophrenia or a related psychotic disorder.
104 . The method of claim 100 , wherein the mental disorder is schizophrenia or a related psychotic disorder.
105 . The method of claim 101 , wherein the mental disorder is schizophrenia or a related psychotic disorder.
106 . The method of claim 98 , wherein the mental disorder is a treatment resistant schizophrenia.
107 . The method of claim 99 , wherein the mental disorder is a treatment resistant schizophrenia.
108 . The method of claim 100 , wherein the mental disorder is a treatment resistant schizophrenia.
109 . The method of claim 101 , wherein the mental disorder is a treatment resistant schizophrenia.
110 . The method of claim 102 , wherein the treatment is targeted at a prodromal, active or residual phase of schizophrenia or related disorder.
111 . The method of claim 103 , wherein the treatment is targeted at a prodromal, active or residual phase of schizophrenia or related disorder.
112 . The method of claim 104 , wherein the treatment is targeted at a prodromal, active or residual phase of schizophrenia or related disorder.
113 . The method of claim 105 , wherein the treatment is targeted at a prodromal, active or residual phase of schizophrenia or related disorder.
114 . The method of claim 106 , wherein the treatment is targeted at a prodromal, active or residual phase of schizophrenia or related disorder.
115 . The method of claim 107 , wherein the treatment is targeted at a prodromal, active or residual phase of schizophrenia or related disorder.
116 . The method of claim 108 , wherein the treatment is targeted at a prodromal, active or residual phase of schizophrenia or related disorder.
117 . The method of claim 109 , wherein the treatment is targeted at a prodromal, active or residual phase of schizophrenia or related disorder.